REG - EKF Diagnostics Hldg - Director/PDMR Shareholding

EKF Diagnostics HoldingsAnnouncement

21/06/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220621:nRSU5538Pa&default-theme=true

RNS Number : 5538P  EKF Diagnostics Holdings PLC  21 June 2022

EKF Diagnostics Holdings plc

("EKF", the "Company" or the "Group")

 

Director/PDMR Shareholding

 

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics
business, announces that it has been notified that on 20 June 2022 Julian
Baines, Non-Executive Deputy Chairman, purchased a total of 11,000 ordinary
shares of 1 pence each in the Company ("Ordinary Shares") at a price of 32.596
pence per Ordinary Share.

 

Following this transaction, Julian Baines' total direct and indirect interest
in the Group is 1,616,288 Ordinary Shares representing approximately 0.36% of
the Group's total issued share capital.

 

The Notification of Dealing Form required in accordance with UK MAR is set out
below.

 

 EKF Diagnostics Holdings plc                             www.ekfdiagnostics.com (http://www.ekfdiagnostics.com)
 Mike Salter, CEO                                          Tel: +44 (0)29 2071 0570
 Marc Davies, CFO

 Singer Capital Markets (Nominated Adviser & Joint Broker)                              Tel: +44 (0)20 7496 3000
 Aubrey Powell / George Tzimas

 Investec Bank plc (Joint Broker)                         Tel: +44 (0)20 7597 4000
 Gary Clarence / Daniel Adams / Ben Farrow

 Walbrook PR Limited               Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com
 Paul McManus / Lianne Applegarth  Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303

 

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Julian Baines

 2    Reason for the notification

 a)   Position/status                                              Non-Executive Deputy Chairman

 b)   Initial notification /Amendment                              Initial Notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         EKF Diagnostics Holdings plc

 b)   LEI                                                          213800DXTF3EAUK1AR05

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Ordinary Shares of £0.01 each

      Identification code                                          GB0031509804

 b)   Nature of the transaction                                    Purchase of Ordinary Shares

 c)   Price(s) and volume(s)

                                                                                     Price(s)          Volume(s)
                                                                                     32.596 pence      11,000

 d)   Aggregated information

      - Aggregated volume                                          N/A - Single Transaction

      - Price

 e)   Date of the transaction                                      20 June 2022

 f)   Place of the transaction                                     London Stock Exchange - AIMX

 

 

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com
(http://www.ekfdiagnostics.com) )

EKF is a leading global diagnostics business with custom manufacturing
facilities across sites in the US, UK and Europe for a variety of life science
products. EKF is focussed on the following areas:

 

 Point-of-Care             Providing a portfolio of Point-of-Care analysers and consumables, particularly
                           for use in the area of Hematology and Diabetes, for use in hospital and
                           research laboratories, doctor's offices, blood banks and for in-field anaemia
                           screening programmes. EKF has an estimated 80,000 hemoglobin, hematocrit,
                           HbA1c, glucose and lactate analysers in regular use across more than 100
                           countries.

 Central Laboratory        Clinical chemistry, Small lab analysers, Centrifuges

                           Beta-Hydroxybutyrate (β-HB) LiquiColor, Glycates Albumin, Glycated Serum
                           Protein, Nitro-tab, Procalcitonin

 Life Sciences             Enzyme fermentation, Custom products and Bulk fermentation

 Contract Manufacturing    Bulk formulation, Sample collection kits, Private labelling, Molecular and
                           forensic kits

 Laboratory Services       In September 2021, EKF completed the acquisition of Advanced Diagnostic
                           Laboratory LLC ("ADL Health"), a Texas based testing laboratory certified
                           under the Clinical Laboratory Improvement Amendments ("CLIA") for high
                           complexity testing. The laboratory provides testing for a variety of clinical,
                           forensic and microbiological sample types using a range of analytical
                           techniques. This acquisition positions EKF as a leading 'one stop' provider of
                           diagnostic products and services from sample collection to results.

 

EKF's growth strategy to 2024 and beyond can be summarised as:

 •    continuing innovation in products and services in Point-of-Care, Central
      Laboratory and Life Sciences leveraging new and existing routes to market and
      relationships;
 •    investment in expanded production and kitting capabilities to offer a suite of
      diagnostic Contract Manufacturing solutions to third party businesses;
 •    expansion of CLIA Laboratories Testing offering, building on the acquired
      capabilities in ADL Health; and
 •    concluding complementary earnings-enhancing acquisitions with key strategic
      value.

 

EKF will also continue to generate enhanced shareholder value through:

 •    a progressive dividend policy; and
 •    its agreement with Mount Sinai Innovation Partners ("MSIP"), which allows us
      advanced access to innovative commercial opportunities and where we can build
      on the ongoing successes of Renalytix plc, Verici Dx plc and Trellus Health
      plc.

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHBCGDLIXDDGDG